The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A review of the clinical pharmacology of methamphetamine
Abstract
Aims To examine the literature regarding clinical pharmacokinetics, direct effects and adverse clinical outcomes associated with methamphetamine use. Methods Relevant literature was identified through a PubMed search. Additional literature was obtained from relevant books and monographs. Findings and conclusions The mean elimination half‐life for methamphetamine is approximately 10 hours, with considerable inter‐individual variability in pharmacokinetics. Direct effects at low‐to‐moderate methamphetamine doses (5–30 mg) include arousal, positive mood, cardiac stimulation and acute improvement in cognitive domains such as attention and psychomotor coordination. At higher doses used typically by illicit users (≥50 mg), methamphetamine can produce psychosis. Its hypertensive effect can produce a number of acute and chronic cardiovascular complications. Repeated use may induce neurotoxicity, associated with prolonged psychiatric symptoms, cognitive impairment and an increased risk of developing Parkinson's disease. Abrupt cessation of repeated methamphetamine use leads to a withdrawal syndrome consisting of depressed mood, anxiety and sleep disturbance. Acute withdrawal lasts typically for 7–10 days, and residual symptoms associated with neurotoxicity may persist for several months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Dopamine, learning and motivation.
Wise, R. A. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1406 · Cited by 3,379
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Ding, Y.-S., Sedler, M., Logan, J., Franceschi, D., Gatley, J., Hitzemann, R., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2015 · Cited by 916
A functional neuroanatomy of hallucinations in schizophrenia
Silbersweig, D. A., Stern, E., Frith, C., Cahill, C., Holmes, A., Grootoonk, S., Seaward, J., McKenna, P., Chua, S. E., Schnorr, L., et al. (1995) · Nature · doi:10.1038/378176a0 · Cited by 906
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria
Drevets, W. C., Gautier, C., Price, J. C., Kupfer, D. J., Kinahan, P. E., Grace, A. A., Price, J. L., & Mathis, C. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01038-6 · Cited by 706
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602 · cited 1×
“Signs of PD are associated with striatal DAT deficits of 47% [131], but DAT deficits among recently abstinent methamphetamine users are typically 20–30% of normal levels [104,105,112,131].”
BackgroundStall, R., Paul, J. P., Greenwood, G., Pollack, L. M., Bein, E., Crosby, G. M., Mills, T. C., Binson, D., Coates, T. J., & Catania, J. A. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.961115896.x · Cited by 587
The nature, time course and severity of methamphetamine withdrawal
McGregor, C., Srisurapanont, M., Jittiwutikarn, J., Laobhripatr, S., Wongtan, T., & White, J. M. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01160.x · Cited by 458 · cited 6×
“Where observed, impaired sleep quality during later withdrawal has been associated with reduced clear-headedness upon waking, suggesting a link between sleep, mood and cognitive function during methamphetamine withdrawal [85].”
BackgroundInfluential
Cited by
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 498
Toxicity of amphetamines: an update
Carvalho, M., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., Remião, F., Carvalho, F., & Bastos, M. D. L. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0815-5 · Cited by 431
Impact of methamphetamine on infection and immunity
Salamanca, S. A., Sorrentino, E. E., Nosanchuk, J. D., & Martinez, L. R. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00445 · Cited by 116
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
A brief history of oxytocin and its role in modulating psychostimulant effects
Carson, D. S., Guastella, A. J., Taylor, E. R., & McGregor, I. S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112473788 · Cited by 105
Metadata
- Authors
- Cruickshank, C. C., & Dyer, K. R.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2009-06-04
- Volume
- 104
- Issue
- 7
- Pages
- 1085-1099
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2052464626
- Cited by
- 769
- References
- 19
- FWCI
- 17.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of the clinical pharmacology of methamphetamine. https://app.cochat.ai/papers/10.1111/j.1360-0443.2009.02564.x
- The paper
- Cruickshank, C. C., & Dyer, K. R. (2009). A review of the clinical pharmacology of methamphetamine. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02564.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
